PGEN News and Press, Precigen Inc. From 08/08/22

The following slide deck was published by Precigen, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Precigen, Inc. 2022 Q2 - Results - Earnings Call Presentation

Precigen press release ( NASDAQ: PGEN ): Q2 GAAP EPS of -$0.09 beats by $0.05 . Revenue of $2.91M (-23.8% Y/Y). "The transaction to sell Trans Ova Genetics, which is expected to close in Q3 2022, will provide Precigen with $170 million in cash up-front and up to a ...

Precigen Reports Second Quarter and First Half 2022 Financial Results PR Newswire – Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T ® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; ...

Major earnings expected after the bell on Monday include: 3D Systems ( DDD ) Lemonade ( LMND ) Novavax ( NVAX ) Take-Two Interactive Software ( TTWO ) Upstart Holdings ( UPST ) For further details see: Notable earnings after Monday's close...

Precigen ( NASDAQ: PGEN ) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.14 (-40.0% Y/Y) and the consensus Revenue Estimate is $22.54M (-32.9% Y/Y). Over the last 3 months, EPS estimates have se...

Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th PR Newswire GERMANTOWN, Md. , Aug. 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene an...

Gainers: Inspira Technologies Oxy ( IINN ) +98% . Cano Health CANO +18% . Veru VERU +16% . Amylyx Pharmaceuticals ( AMLX ) +13% . Equillium ( EQ ) +12% . Losers: Applied Molecular Transport AMTI -26% . HTG Molecular D...

Gainers: Alpha Tau Medical ( DRTS ) +42% . Precigen ( PGEN ) +20% . Amylyx Pharmaceuticals ( AMLX ) +18% . bluebird bio ( BLUE ) +13% . Talaris Therapeutics ( TALS ) +11% . Losers: Revelation Biosciences ( REVB ...

The shares of the development stage biotech Precigen ( NASDAQ: PGEN ) climbed in the pre-market Tuesday after the company announced an agreement to sell its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, to URUS. Per the terms, URUS, a holding company focused ...

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics PR Newswire – Precigen enters into agreement to sell wholly-owned subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash and up to $10 million earn-out ...